| Bioactivity | BM635 mesylate is a MmpL3 inhibitor with outstanding anti-mycobacterial activity. BM635 mesylate has a MIC50 of 0.6 μM against M. tuberculosis H37Rv. BM635 mesylate significantly improves the bioavailability compared to free-base BM635[1]. |
| Target | MIC50: 0.08 μM (M. tuberculosis H37Rv) |
| In Vivo | BM635 mesylate (oral administration; 50 mg/kg) results in gradual elevations in blood up to a Cmax of 2970 ng/ml with Tmax of 0.8 hour, it has a improved solubility compared to BM635 hydrochloride. In addition, BM635-Mes significantly improves the bioavailability with a AUC 4 times higher than free-base BM635[1]. |
| Name | BM635 mesylate |
| Formula | C26H33FN2O4S |
| Molar Mass | 488.61 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Poce G, et al. Pharmaceutical salt of BM635 with improved bioavailability. Eur J Pharm Sci. 2017 Mar 1;99:17-23. |